Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP002 in Combination With Chemotherapy for Extensive Stage Small Cell Lung Cancer
NCT04740021Phase 2Unknown
- Sponsor
- Taizhou Houde Aoke Technology
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LP002 in small cell lung cancer (SCLC), sponsored by Taizhou Houde Aoke Technology. Status: unknown.
02
Drugs
LP002
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04740021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740021.